After losing its powerhouse partner, IGM Biosciences closed “most” of its labs and offices and initiated a strategic review ...

The FDA expects to fully integrate its AI approach by June 30, though its different centers have been instructed to start the ...

The missed PDUFA adds to a string of delays at the FDA in recent weeks, including at least two other missed target action ...

The company discontinued development last month of its most mature asset, RLYB212, following disappointing mid-stage ...

Year-over-year BioSpace data show biopharma professionals faced increased competition for fewer employment opportunities ...

The cell engineering company, co-founded by oncologist and writer Siddhartha Mukherjee, does not see a path forward for its ...

The independent experts will meet on May 22 to discuss updates to the COVID-19 vaccine for the upcoming season.

After more than a month of speculation over how the FDA will rule on Novavax’s application for an updated formulation of its ...

The UCSF professor and frequent YouTube poster has criticized COVID-19 vaccine mandates as well as the accelerated approval ...

In this episode of Denatured BioSpace's head of insights Lori Ellis discusses the public health consequences of vaccine ...

The biopharma job market likely won’t turn around until 2026, according to two industry experts. Both cited a need for more ...

Takeda’s Julie Kim argues that Trump’s idea to match drug prices to that of other countries could cost the industry up to $1 ...